These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29276997)

  • 1. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.
    Chae YK; Galvez C; Anker JF; Iams WT; Bhave M
    Cancer Treat Rev; 2018 Feb; 63():116-121. PubMed ID: 29276997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients.
    Maggiore U; Pascual J
    Adv Chronic Kidney Dis; 2016 Sep; 23(5):312-316. PubMed ID: 27742386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade for organ-transplant recipients with cancer: A review.
    Rünger A; Schadendorf D; Hauschild A; Gebhardt C
    Eur J Cancer; 2022 Nov; 175():326-335. PubMed ID: 36191571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
    Fisher J; Zeitouni N; Fan W; Samie FH
    J Am Acad Dermatol; 2020 Jun; 82(6):1490-1500. PubMed ID: 31302190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
    Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
    Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
    Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.
    d'Izarny-Gargas T; Durrbach A; Zaidan M
    Am J Transplant; 2020 Sep; 20(9):2457-2465. PubMed ID: 32027461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
    Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
    Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
    Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.